{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:23:56Z","timestamp":1789025036532,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust NZ J Obst Gynaeco"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Haemolytic disease of the fetus\/newborn secondary to clinically significant non\u2010Rhesus\u2010D antibodies has risen in importance since the advent of immunoprophylactic anti\u2010D administration to Rhesus\u2010D negative women. Of interest is the incidence of these antibodies in Rhesus\u2010D positive women, who receive less frequent antenatal alloantibody screening. This is of particular concern if the antibodies arise late in pregnancy and may go undetected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the proportion of Rhesus\u2010D positive pregnant women with late developing clinically significant antibodies for haemolytic disease of the fetus\/newborn, and whether these resulted in adverse fetal outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A retrospective analysis over a 12\u2010month period at a tertiary hospital in the Northern Territory. Group and antibody screen results in addition to clinical data regarding pregnancy\/newborn were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010four of 2612 women (2.5%) had red blood cell antibodies detected during their pregnancy. Of these, 21 clinically significant antibodies were detected in 19 women (0.7% of initial cohort). The most common antibody detected was anti\u2010c (28.5%). In six of these women (0.23% of initial cohort), the antibodies were late developing. Mild jaundice was noted in three newborns with phototherapy required in one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although clinically significant antibodies were detected during pregnancy, and in a small proportion of cases as a late developing antibody undetected in the first trimester screening, clinical outcomes for the newborn were mild. As such, the cost of retesting all Rhesus\u2010D positive pregnant women in the third trimester would be considerable and unlikely to result in any meaningful clinical benefit.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajo.12750","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T15:42:20Z","timestamp":1511970140000},"page":"514-517","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The incidence and outcome of clinically significant antibodies detected in Rhesus\u2010D positive pregnant women of the Northern Territory"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-5049","authenticated-orcid":false,"given":"Lauren","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Haematology Royal Darwin Hospital  Darwin Northern Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Szabo","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Darwin Hospital  Darwin Northern Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12265"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.01984.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-134"},{"key":"e_1_2_5_5_1","first-page":"528","article-title":"Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non\u2010RhD antibodies","volume":"11","author":"Dajak S","year":"2013","journal-title":"Blood Transfus"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.75963"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016349509021175"},{"key":"e_1_2_5_8_1","unstructured":"ANZSBT.org.Australia: Guidelines for Blood Grouping & Antibody Screening in the Antenatal & Perinatal Setting. [Accessed 30 July 2017.]. Available from URL:www.anzsbt.org.au"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12299"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1981.tb00948.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2008.02.007"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701448438"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33393174447.x"},{"key":"e_1_2_5_14_1","unstructured":"ANZSBT.org.Australia: Guidelines for Transfusion and Immunohaematology Laboratory Practice. [Accessed 30 July 2017.]. Available from URL:www.anzsbt.org.au"},{"key":"e_1_2_5_15_1","first-page":"8","article-title":"Late developing red cell antibodies in pregnancy","volume":"13","author":"Thompson S","year":"2003","journal-title":"Transfus Med"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03006.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2002.810506.x"},{"key":"e_1_2_5_18_1","first-page":"1145","article-title":"Is a third\u2010trimester antibody screen in Rh+ women necessary?","volume":"5","author":"Rothenberg JM","year":"1999","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767050601123317"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04442-1"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1986.tb07828.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.08.003"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767050412331312260"}],"container-title":["Australian and New Zealand Journal of Obstetrics and Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajo.12750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajo.12750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:07:40Z","timestamp":1694934460000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/ajo.12750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/ajo.12750"],"URL":"https:\/\/doi.org\/10.1111\/ajo.12750","archive":["Portico"],"relation":{},"ISSN":["0004-8666","1479-828X"],"issn-type":[{"value":"0004-8666","type":"print"},{"value":"1479-828X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]},"assertion":[{"value":"2017-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}